General
Preferred name
debrisoquine
Synonyms
DEBRISOQUIN SULFATE ()
Debrisoquin HI ()
DEBRISOQUIN ()
Debrisoquine sulfate ()
Debrisoquin (hydroiodide) ()
Debrisoquine (hydroiodide) ()
Isocaramidine (hydroiodide) ()
Ro 5-3307/1 (hydroiodide) ()
RO 5-3307/1 ()
Debrisoquin sulphate ()
Declinax ()
NSC-139330 ()
RO-5-3307/1 ()
Debrisoquin Sulfate ()
Debrisoquina ()
Debrisoquine ()
Debrisoquin hydriodide ()
Debrisoquin (hemisulfate ()
Debrisoquin hydriodide ()
P&D ID
PD009366
CAS
581-88-4
1131-64-2
1052540-65-4
Tags
available
drug candidate
drug
First approval
1965
Drug indication
Hypertension
Drug Status
approved
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Debrisoquin (hydroiodide) is the hydrochloride form of Debrisoquin (HY-B1624). Debrisoquin is a TMPRSS2?inhibitors that inhibits?SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner. Debrisoquin can be used for?antiviral?research[1].
PRICE 30
DESCRIPTION Debrisoquin hydriodide (1,2,3,4-tetrahydroisoquinoline-2-carboximidamide hydroiodide) has antioxidant, anti-inflammatory and neuroprotective properties. It has also been found to modulate the activity of certain neurotransmitters, including dopamine and serotonin, making it a promising candidate for the treatment of neurological disorders such as Parkinson's disease and depression.
DESCRIPTION Antihypertensive; metabolized to tetrahydroisoquinoline (TIQ) which may play a role in the induction of Parkinson's Disease (LOPAC library)
DESCRIPTION Debrisoquine is an adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. It is used for the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension. (Enamine Bioactive Compounds)
Cell lines
0
Organisms
2
Compound Sets
19
Cayman Chemical Bioactives
29568
ChEMBL Drugs
CHEMBL1593558
CHEMBL169901
Drug Repurposing Hub
DrugBank
DB04840
DrugBank Approved Drugs
DB04840
DrugCentral
788
DrugCentral Approved Drugs
788
DrugMAP
DMC50ME
DrugMAP Approved Drugs
DMC50ME
DrugMatrix
Enamine Bioactive Compounds
EBC-15022
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS102043
LOPAC library
MedChem Express Bioactive Compound Library
HY-W195509
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
The Spectrum Collection
External IDs
72
Properties
(calculated by RDKit )
Molecular Weight
175.11
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
2
Rotatable Bonds
0
Ring Count
2
Aromatic Ring Count
1
cLogP
0.94
TPSA
53.11
Fraction CSP3
0.3
Chiral centers
0.0
Largest ring
6.0
QED
0.46
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
hypertension
Target
SLC6A2
SARS-CoV
Ser/Thr Protease
MOA
adrenergic neuron blocker
Therapeutic Class
Antihypertensive Agents
Pathway
Anti-infection
Metabolic Enzyme/Protease
Source data